ArticleJournal of translational medicine2026
Low-dose MyoAAV 2A-mediated delivery of engineered micro-utrophin achieves pan- muscle tissue distribution with elevated muscle function in Duchenne muscular dystrophy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe pathogenesis of Duchenne muscular dystrophy (DMD) is driven by a deficiency of functional dystrophin. Although gene therapy is a promising strategy, current approaches face substantial challenges in balancing therapeutic efficacy with toxicity, largely owing to the requirement for high-dose adeno-associated virus (AAV) administration.
methodsWe employed a low-dose strategy in neonatal mdx mice, using a muscle-targeted MyoAAV 2 A capsid to deliver a rationally designed, codon-optimized micro-utrophin construct (ΔR4-R22/ΔC + H3/H4) at 1 × 10¹² vg/kg via intraperitoneal injection. Four weeks post-injection, micro-utrophin expression and localization, as well as γ- and α-sarcoglycan recruitment, were assessed by western blotting and immunofluorescence. Vector genome distribution was quantified by real-time quantitative PCR. Tissue histology was evaluated using Evans blue dye uptake, H&E staining, and Masson's trichrome staining. Muscle function was measured by grip strength and treadmill exercise tests. Serum biomarkers of cardiac injury, heart failure, and systemic inflammation were detected by ELISA.
resultsRobust micro-utrophin expression was detected in skeletal muscles, diaphragm, and myocardium, with minimal off-target expression in the liver. Sarcolemmal localization and functional recruitment of γ- and α-sarcoglycan confirmed restoration of the dystrophin-glycoprotein complex. In treated animals, serum creatine kinase levels, Evans blue dye uptake, and central nucleation in multiple muscles were significantly reduced, accompanied by improvements in relative grip strength, running time, and distance to exhaustion. No cardiac or hepatic toxicity was observed, as indicated by unchanged cTnI, NT-proBNP, ALT, and AST levels. Additionally, serum IL-6 and C5a concentrations were significantly decreased, and fibrosis and inflammation in the diaphragm and myocardium were markedly attenuated.
conclusionsThese findings demonstrate that combining a functional micro-utrophin construct with an advanced muscle-tropic MyoAAV 2 A capsid constitutes a promising strategy to overcome the efficacy-toxicity trade-off that has hindered the clinical translation of DMD gene therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.